Role of the autotaxin–lysophosphatidate axis in the development of resistance to cancer therapy
Autotaxin (ATX) is a secreted enzyme that hydrolyzes lysophosphatidylcholine to produce lysophosphatidate (LPA), which signals through six G-protein coupled receptors (GPCRs). Signaling through LPA is terminated by its degradation by a family of three lipid phosphate phosphatases (LPPs). LPP1 also a...
Gespeichert in:
Veröffentlicht in: | Biochimica et biophysica acta. Molecular and cell biology of lipids 2020-08, Vol.1865 (8), p.158716-158716, Article 158716 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Autotaxin (ATX) is a secreted enzyme that hydrolyzes lysophosphatidylcholine to produce lysophosphatidate (LPA), which signals through six G-protein coupled receptors (GPCRs). Signaling through LPA is terminated by its degradation by a family of three lipid phosphate phosphatases (LPPs). LPP1 also attenuates signaling downstream of the activation of LPA receptors and some other GPCRs. The ATX-LPA axis mediates a plethora of activities such as cell proliferation, survival, migration, angiogenesis and inflammation, which perform an important role in facilitating wound healing. This wound healing response is hijacked by cancers where there is decreased expression of LPP1 and LPP3 and increased expression of ATX. This maladaptive regulation of LPA signaling also causes chronic inflammation, which has been recognized as one of the hallmarks in cancer. The increased LPA signaling promotes cell survival and migration and attenuates apoptosis, which stimulates tumor growth and metastasis. The wound healing functions of increased LPA signaling also protect cancer cells from effects of chemotherapy and radiotherapy. In this review, we will summarize knowledge of the ATX-LPA axis and its role in the development of resistance to chemotherapy and radiotherapy. We will also offer insights for developing strategies of targeting ATX-LPA axis as a novel part of cancer treatment. This article is part of a Special Issue entitled Lysophospholipids and their receptors: New data and new insights into their function edited by Susan Smyth, Viswanathan Natarajan and Colleen McMullen.
•LPA signaling is balanced by LPA formation by ATX and its degradation by the LPPs plus the expression of LPA receptors.•LPP1 also attenuates signaling downstream of the activation of LPA receptors and some other GPCRs.•LPA signaling increases productions of COX-2 and inflammatory cytokines/chemokines, which further increase ATX production.•LPA signaling hijacked by cancers promotes tumor development and protects cancer cells from chemotherapy and radiotherapy.•LPA signaling also promotes radiation-induced fibrosis. |
---|---|
ISSN: | 1388-1981 1879-2618 |
DOI: | 10.1016/j.bbalip.2020.158716 |